Thirty business days below $1 trigger a Nasdaq notice for Nano-X Imaging (Nasdaq: NNOX).
Nano-X Imaging Ltd. (NNOX) has received a Nasdaq notice for non-compliance with the minimum bid-price requirement, as its ordinary shares traded below $1.00 for 30 consecutive business days. The company has until March 29, 2027, to regain compliance by having its closing bid price meet or exceed $1.00 for at least 10 consecutive business days. NNOX is monitoring the situation and considering options, with the possibility of an additional grace period if it transfers its listing to the Nasdaq Capital Market.
Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts
Nanox.AI is expanding its artificial intelligence business by focusing on bone health solutions and optimizing its imaging AI framework. The company has signed a reseller agreement in the UK for its HealthOST bone solution and is collaborating with Intel to enable local inference on hospital hardware, reducing reliance on cloud services. These initiatives aim to utilize routine CT scan data more effectively to diagnose conditions like vertebral fragility fractures that might otherwise go unnoticed.
Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts
Nanox.AI is advancing its medical imaging analytics business by expanding its commercial reach and optimizing its AI framework. The company signed an exclusive three-year UK reseller agreement with Vertec Scientific for its HealthOST bone solution and is collaborating with Intel to enable local inference of its AI on hospital hardware. These efforts aim to address the issue of undiagnosed conditions, such as vertebral fragility fractures, by identifying additional anatomical information from routine CT scans.
Annual meetings must occur once a calendar year and within 15 months at Nano-X Imaging (NNOX).
Nano-X Imaging Ltd. shareholders approved amended articles of association at their annual general meeting on September 29, 2026. The new rules mandate an annual general meeting once per calendar year and within 15 months of the previous one, and set a special-resolution threshold at 66 2/3% of votes cast. These changes impact corporate governance and shareholder engagement for the company.
Finding What the Scan Already Captured: Nanox Advances Its AI Business on Two Fronts
Nanox.AI, a subsidiary of Nano-X Imaging Ltd., is expanding its medical imaging analytics business by addressing the issue of undiagnosed vertebral fragility fractures in the UK. They have signed an exclusive three-year reseller agreement with Vertec Scientific for their HealthOST bone solution and are optimizing their AI framework with Intel to run locally on hospital hardware, reducing reliance on cloud infrastructure. These initiatives aim to leverage routine CT scans to identify additional clinical findings that might otherwise be overlooked.
Nano-X Imaging Ltd. (NNOX) Stock Price, News, Quote & History
This article provides detailed financial information and company overview for Nano-X Imaging Ltd. (NNOX). It includes stock price performance, key financial metrics, recent news, analyst ratings, and a description of the company's medical imaging solutions and services. The data indicates significant negative returns over various periods and highlights the company's focus on tomographic imaging and AI applications in healthcare.
Nanox's Integrated Imaging Ecosystem: Expanding Access to 3D Imaging and Diagnostics
Nanox is addressing the global lack of access to medical imaging technology by developing an integrated platform, centered around its FDA-cleared Nanox.ARC system. This platform aims to extend 3D imaging capabilities to outpatient facilities and clinics, overcoming the infrastructure and cost barriers of traditional high-end systems. The company reported second-quarter revenue of $4.2 million as it begins to commercialize its ecosystem, which also includes AI, cloud, marketplace, and health IT components.
Nanox’s Integrated Imaging Ecosystem: Expanding Access to 3D Imaging and Diagnostics
Nanox is addressing the global inequality in access to medical imaging technology by developing an integrated platform. Their system, centered around Nanox.ARC, aims to extend 3D imaging capabilities to outpatient facilities and clinics, lowering adoption barriers. The company reported second-quarter revenue of $4.2 million as commercial activities begin to grow.
Nanox’s Integrated Imaging Ecosystem: Expanding Access to 3D Imaging and Diagnostics
Nanox is addressing the global inequality in access to advanced medical imaging by developing an integrated platform that extends 3D imaging capabilities beyond major hospitals to outpatient facilities and clinics. Their Nanox.ARC system, an FDA-cleared multi-source digital tomosynthesis system, is central to this effort, aiming to lower barriers to adoption and improve diagnostics in underserved areas. The company reported second-quarter revenue of $4.2 million as commercial activities begin to build.
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Nano-X Imaging Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ: NNOX) for alleged violations of securities laws. The lawsuit claims that Nanox made false and misleading statements regarding its 510(k) application for the Nanox.ARC, which was reportedly deficient and unlikely to be approved by the FDA. Investors who purchased securities between June 17, 2021, and August 18, 2021, and suffered losses are encouraged to contact the firm before December 6, 2021.
Bearish: Analysts Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue and EPS Estimates
Analysts have significantly cut their revenue and earnings per share estimates for Nano-X Imaging Ltd. (NASDAQ:NNOX) following its recent earnings report. The consensus revenue estimate for 2026 has been lowered by 47% to US$345m, and the EPS estimate has been reduced by 14% to US$0.02. This bearish sentiment from analysts suggests a potential reevaluation of the company's growth trajectory and profitability expectations.
News Flash: 2 Analysts Think Nano-X Imaging Ltd. (NASDAQ:NNOX) Earnings Are Under Threat
Two analysts have significantly revised down their forecasts for Nano-X Imaging Ltd. (NNOX) for 2026, cutting both revenue and earnings per share estimates. They now project revenues of US$22 million and increased losses of US$1.31 per share, leading to a 19% reduction in the consensus price target to US$4.13. Despite the downgrade, the company's projected annual revenue growth of 103% still significantly outpaces the industry average of 4.9%.
Nano-X (NASDAQ: NNOX) calls one shareholder vote critical to its financial viability
Nano-X Imaging Ltd. (NNOX) adjourned its 2026 Annual General Meeting due to a lack of quorum and will reconvene on September 29, 2026. The company is urging shareholders to vote "FOR" Proposal 2, which seeks to increase authorized share capital, stating it is "critical to the financial viability" of the company. NNOX also disclosed that its cash resources as of June 30, 2026, raise substantial doubt about its ability to continue as a going concern, highlighting the importance of securing financing through additional authorized capital.
Nano-X Imaging (NNOX) CEO boosts stake with 10,000-share buy
Nano-X Imaging Ltd. CEO Erez Meltzer purchased 10,000 ordinary shares of NNOX at $0.69 per share on September 15, 2026, increasing his indirect holdings to 65,443 shares. He also directly holds 60,584 ordinary shares and various stock options. This transaction was not made under a Rule 10b5-1 trading plan.
Nano-X Imaging Q2 Earnings Call Highlights
Nano-X Imaging (NNOX) reported a 37% year-over-year revenue increase in Q2 2026, reaching $4.2 million, driven by teleradiology and health IT. Despite this growth, the company posted a significant GAAP net loss of $55.5 million due to a $40.7 million impairment charge on AI intangible assets and is undertaking restructuring efforts to reduce costs and extend its cash runway. Nano-X is also expanding its commercialization efforts for the Nanox.ARC imaging system through partnerships and installations, while also advancing its AI solutions and exploring new reimbursement pathways.
Nano-X Imaging (NNOX) discloses cash shortfall and going-concern risk
Nano-X Imaging (NNOX) reported a 45% increase in first-half 2026 revenue to $8.5 million, but its net loss widened significantly to $69.8 million, primarily due to a $40.7 million impairment charge on AI-related intangible assets. The company disclosed a "going concern" warning, stating that its existing cash and equivalents of $31.0 million as of June 30, 2026, are insufficient to fund operations for at least one year. While subsequent capital raises of $8.5 million gross have occurred, the company is still actively seeking additional financing and implementing cost reduction strategies.
Nano-X Imaging (NNOX) Signs Nanox.ARC Distribution Agreement for Costa Rica
Nano-X Imaging (NNOX) has signed a distribution agreement with SOLME RC, S.A. for Costa Rica to market and support its Nanox.ARC system, which is designed to expand access to 3D medical imaging. SOLME will manage marketing, distribution, installation, training, and technical support. This agreement marks Costa Rica as Nanox's third Latin American market this year, following Argentina and Peru, with commercialization subject to regulatory registration including a six-month proof-of-concept period.
Nanox signs distribution deal for imaging system in Costa Rica
Nanox Imaging Ltd. has signed a distribution agreement with SOLME RC, S.A. to market its Nanox.ARC imaging system in Costa Rica. This partnership will see SOLME handle the marketing, distribution, installation, training, and technical support for the 3D medical imaging system. Costa Rica is the third Latin American market Nanox has entered this year, following Argentina and Peru, pending a regulatory registration process.
Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica
Nano-X Imaging Ltd. (Nanox) has signed a distribution agreement with SOLME RC, S.A. to market and support its Nanox.ARC system in Costa Rica. This partnership marks Nanox's third expansion into the Latin American market this year, following agreements in Argentina and Peru. SOLME will handle marketing, distribution, installation, training, and technical support for the Nanox.ARC, a multi-source digital tomosynthesis system aimed at expanding access to 3D medical imaging.
Earnings call transcript: Nano-X Imaging Q2 2026 revenue miss sparks sharp premarket drop
Nano-X Imaging reported Q2 2026 revenue of $4.2 million, missing the $5.54 million forecast, and a widened GAAP net loss of $55.5 million due to a $40.7 million impairment charge, causing its shares to drop 19.3% in premarket trading. Despite year-over-year revenue growth of 37%, the company acknowledged slower-than-expected commercialization but highlighted progress in system placements, AI installations, and a new CMS reimbursement code for its AI Cardio solution. Management also discussed cost-saving measures and plans to raise additional capital to support ongoing operations and future growth.
Full Transcript: Nano X Imaging Q2 2026 Earnings Call
Nano X Imaging reported Q2 2026 revenue of $4.2 million, a 37% increase year-over-year, driven by the consolidation of Nano X Health IT and growth in teleradiology services. The company is focusing on commercialization and cost-cutting, including workforce reductions in South Korea and Israel, and has raised $8.5 million to extend its cash runway. Key developments include new distribution partnerships, the first Nanox Imaging Network installation in Philadelphia, and progress in AI solutions with new sales agreements and a potential reimbursement pathway.
Nanox signs distribution deal with Associated X-Ray Imaging By Investing.com
Nano-X Imaging Ltd. (NASDAQ:NNOX) announced that its U.S. subsidiary, Nanox Impact Inc., has partnered with Associated X-Ray Imaging Corp. for the distribution of its FDA-cleared Nanox.ARC system across New England. This agreement is part of Nanox's strategy to expand its commercial footprint in the U.S. by leveraging regional distribution partnerships for its multisource 3D digital tomosynthesis system. Associated X-Ray Imaging will be responsible for marketing, distribution, and support, utilizing its existing service infrastructure and extensive experience in providing medical imaging equipment.
Nanox signs distribution deal with Associated X-Ray Imaging By Investing.com
Nano-X Imaging Ltd. (NASDAQ:NNOX) announced a distribution agreement with Associated X-Ray Imaging Corp. to deploy its Nanox.ARC system across New England. This partnership aims to expand Nanox's U.S. commercial footprint and leverage Associated X-Ray Imaging's regional presence for marketing, distribution, and support of the FDA-cleared 3D digital tomosynthesis system. The deal is a key part of Nanox's strategy to broaden its distribution network for the Nanox.ARC in targeted U.S. regions.
Nano-X Imaging (NNOX) to Report Second-Quarter 2026 Financial Results Sept. 9
Nano-X Imaging (NNOX) announced it will report its financial results for the second quarter of 2026 before market open on September 9, 2026. CEO Erez Meltzer and CFO Guy Nathanzon will host a conference call at 8:30 a.m. ET to discuss the results and provide a business update. A live webcast will also be available on the company's investor relations website.
Nano-X Imaging (NASDAQ: NNOX) to Report Second-Quarter 2026 Financial Results Sept. 9
Nano-X Imaging (NASDAQ: NNOX) will report its second-quarter 2026 financial results on September 9, 2026, before market open. CEO Erez Meltzer and CFO Guy Nathanzon will host a conference call and live webcast to discuss the results and provide a business update. The company specializes in medical imaging technology, aiming to transition to preventive healthcare through an integrated platform.
NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Nano-X Imaging Ltd. (NASDAQ: NNOX), announcing a securities class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. made materially false or misleading statements regarding its operational efficiency, product demand, and increased operating expenses, leading to artificial inflation of its stock. Investors who purchased NNOX shares between March 31, 2025, and April 17, 2026, are encouraged to contact the firm, with a lead plaintiff deadline of August 11, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nano-X Imaging Ltd. - NNOX
Pomerantz LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. (NNOX) on behalf of its investors. This investigation follows Nano-X's announcement of a $33.4 million net loss for Q4 2025, primarily due to a $17.5 million impairment charge related to a restructuring at its Korean chip manufacturing facility. Additionally, the company announced that its CFO would be stepping down, leading to a 24.39% drop in Nano-X's stock price.
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) who purchased securities between March 31, 2025, and April 17, 2026, about the August 11, 2026 lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Nano-X made false and misleading statements regarding operational efficiency, demand for its products, and increased operating expenses, leading to investor damages. Investors are encouraged to contact the Rosen Law Firm to join the class action.
Nanox AI secures UK reseller deal for bone health software
Nanox AI, a subsidiary of Nanox Imaging Ltd., has entered into an exclusive three-year reseller agreement with Vertec Scientific Ltd. for its HealthOST bone solution in the UK. HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to assess musculoskeletal disease of the spine, including osteoporosis, without requiring additional imaging or patient time. This deal aims to expand the reach of Nanox AI's technology in the UK market, following a recommendation by the National Institute for Health and Care Excellence for similar AI technologies in opportunistic detection of vertebral fragility fractures.
Nanox and Vertec Scientific Enter Exclusive Sales Reseller
Nanox AI has partnered with Vertec Scientific Ltd. through an exclusive sales reseller agreement to commercialize its Nanox.AI bone solution (HealthOST) in the United Kingdom. This three-year agreement includes minimum annual license commitments and aims to expand the reach of AI-driven bone health assessment. HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to detect musculoskeletal diseases like osteoporosis.
Nanox's bone software analyzes routine CT scans without extra radiation or patient time
Nanox's AI subsidiary has signed an exclusive three-year sales reseller agreement with Vertec Scientific for its HealthOST bone solution in the UK. HealthOST is an FDA-cleared and UKCA/CE-marked AI software that analyzes routine CT scans to assess spine-related musculoskeletal diseases like osteoporosis, without requiring additional imaging or radiation. This partnership aims to expand the reach of AI-driven bone health assessment to healthcare providers across the UK, leveraging Vertec Scientific's established presence in DXA and bone health solutions.
Nano-X (NASDAQ: NNOX) warns on cash runway before vote to boost share pool
Nano-X Imaging Ltd. (NASDAQ: NNOX) is holding its 2026 annual general meeting on September 17, 2026, where shareholders will vote on increasing the authorized share capital by 50 million ordinary shares due to the company's limited cash runway. Management disclosed that current cash and equivalents as of March 31, 2026, are insufficient to support operations for at least one year, raising substantial doubt about its ability to continue as a going concern. The proposal aims to provide flexibility for future financing, strategic transactions, equity compensation, and Nasdaq compliance.
Nano-X Imaging faces legal battles ahead of Q3 earnings with expected loss and strong balance sheet.
Nano-X Imaging Ltd. is preparing to report its Q3 earnings, with analysts projecting a loss of $0.16 per share and revenues of $5.38 million. The company is simultaneously dealing with several class-action lawsuits regarding alleged securities law violations. Despite an unprofitable P/E ratio, Nano-X demonstrates financial stability through a low debt-to-equity ratio and a strong current ratio.
NNOX Reiterated by Cantor Fitzgerald -- Price Target Maintained at $5.00
Cantor Fitzgerald has reiterated its Overweight rating for Nano X Imaging (NNOX), maintaining a price target of $5.00, suggesting confidence in the company despite varying analyst opinions. Although NNOX is currently unprofitable, its GF Value of $10.16 indicates it is significantly undervalued by 90.2%. However, its low GF Score of 41/100, especially in profitability and growth, alongside a high Price-to-Sales ratio, presents a mixed picture for investors.
NNOX Q2'26 Earnings: EPS estimate is (0.16) USD
NANO-X IMAGING LTD (NNOX) is expected to announce its Q2'26 earnings on August 18, with an anticipated revenue of 5.39 million USD and an EPS of (0.16) USD. The article provides a detailed table comparing reported and estimated revenue and EPS figures for several quarters, highlighting past surprises.
Nano-X Imaging (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors
Nano-X Imaging Ltd. (NASDAQ: NNOX) announced that its subsidiary Nanox.AI has optimized its medical imaging AI application framework for Intel Core Ultra processors using the Intel OpenVINO toolkit. This optimization enables healthcare facilities to deploy CT imaging AI applications on on-premise edge devices, keeping imaging data within their own infrastructure and bringing AI-enabled insights closer to the point of care. The framework aims to reduce dependence on cloud connectivity and support deployment within existing hospital infrastructure for identifying chronic conditions.
Nano-X Imaging (NASDAQ: NNOX) Optimizes Nanox.AI Medical Imaging Framework for Intel Core Ultra Processors
Nano-X Imaging Ltd. announced that its subsidiary, Nanox.AI Ltd., has optimized its medical imaging AI application framework for Intel Core Ultra processors using the Intel OpenVINO toolkit. This optimization allows healthcare facilities to deploy CT imaging AI applications on on-premise edge devices, keeping imaging data within their own infrastructure. The Nanox.AI solutions analyze CT scans to identify findings correlated with chronic conditions related to cardiac, liver, and bone health, bringing AI-enabled insights closer to the point of care while reducing reliance on cloud connectivity.
NNOX DEADLINE - FINAL REMINDER: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Nano-X Imaging Ltd. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC is issuing a final reminder to stockholders of Nano-X Imaging Ltd. (NASDAQ:NNOX) about a class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. and its officers made false and misleading statements regarding the company's operations and prospects between March 31, 2025, and April 17, 2026. Investors who suffered losses have until August 11, 2026, to request to be appointed as lead plaintiff.
NNOX Shareholder Alert: Nano-X Imaging Ltd. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for Nano-X Imaging Ltd. (NASDAQ: NNOX) investors, announcing a securities class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. made materially false and misleading statements regarding its operational efficiency and product demand, leading to increased operating expenses and potential restructuring charges. Shareholders who purchased NNOX shares between March 31, 2025, and April 17, 2026, are encouraged to contact the firm, with a deadline to seek lead plaintiff appointment by August 11, 2026.
Portnoy Law Firm Announces Class Action on Behalf of Nano-X Imaging Ltd. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Nano-X Imaging Ltd. (NASDAQ: NNOX) who purchased securities between March 31, 2025, and April 17, 2026. The lawsuit alleges that Nano-X overstated its efficiency, experienced misalignment between production and demand, and faced increased operating expenses, leading to misleading public statements. Investors have until August 11, 2026, to file a lead plaintiff motion.
Nano-X Imaging (NNOX) CEO Erez Meltzer adds 9,443 shares via owned company
Nano-X Imaging Ltd. CEO Erez Meltzer indirectly purchased 9,443 Ordinary Shares on August 10, 2026, at $1.03 per share through his wholly-owned company, Oud Nof. This transaction increased Oud Nof's holdings to 45,443 shares, while Meltzer also directly holds 60,584 Ordinary Shares and multiple stock options. The purchase was not made under a Rule 10b5-1 trading plan.
Urgent Deadline for Shareholders who lost money in shares of Nano-X Imaging Ltd. (NASDAQ: NNOX)
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) of a class action lawsuit with a lead plaintiff deadline of today, August 11, 2026. The lawsuit alleges that Nano-X overstated its operational efficiency and product demand, leading to significant financial losses for investors. This follows Nano-X's Q4 2025 financial results which reported a net loss and a $17.5 million impairment charge due to a restructuring initiative.
Nanox.AI Optimizes Medical Imaging AI Application Framework for Intel Core Ultra Processors with OpenVINO
Nanox.AI has optimized its medical imaging AI application framework for Intel Core Ultra processors using Intel’s OpenVINO toolkit. This optimization allows healthcare organizations to deploy CT imaging AI applications on-premise, reducing reliance on cloud connectivity and keeping data within their own infrastructure. The collaboration aims to bring AI-enabled imaging insights closer to the point of care, supporting preventive care management and improving clinical workflows.
NNOX EQUITY ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nano-X Imaging (NNOX) Investors of Securities Class Action Lawsuit Deadline on August 11, 2026
Faruqi & Faruqi, LLP is reminding investors of Nano-X Imaging (NNOX) about a securities class action lawsuit deadline on August 11, 2026. The lawsuit alleges that Nano-X made false and misleading statements regarding its operational efficiency, product demand, and financial health, leading to increased operating expenses and cash burn. Investors who purchased Nano-X securities between March 31, 2025, and April 17, 2026, and suffered losses are encouraged to contact the firm to discuss their legal options and the lead plaintiff process.
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Nano-X Imaging Ltd. (NNOX) for alleged securities fraud, covering the period from March 31, 2025, to April 17, 2026. The lawsuit claims Nano-X made false and misleading statements regarding demand for its products and operational efficiency, leading to increased cash burn due to misalignment with customer demands. Investors who suffered losses during this period are encouraged to contact SBS Law to potentially lead the lawsuit, with a deadline of August 11, 2026, for lead plaintiff appointments.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
Rosen Law Firm is reminding investors of Nano-X Imaging Ltd. (NASDAQ: NNOX) who purchased securities between March 31, 2025, and April 17, 2026, about the August 11, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Nano-X made false and misleading statements regarding its operational efficiency, product demand, and increasing operating expenses and cash burn, leading to investor damages. Investors can join the class action by contacting Rosen Law Firm.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
Rosen Law Firm reminds purchasers of Nano-X Imaging Ltd. (NNOX) securities between March 31, 2025, and April 17, 2026, that the lead plaintiff deadline for a securities fraud lawsuit is August 11, 2026. The lawsuit alleges that Nano-X made false or misleading statements regarding its operational efficiency and demand, leading to increased operating expenses and cash burn. Investors who suffered losses are encouraged to contact Rosen Law Firm to explore their options to lead the class action.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between March 31, 2025, and April 17, 2026, about the August 11, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Nano-X made false and misleading statements regarding its operational efficiency, product demand, and financial health, leading to increased operating expenses and cash burn. Investors are encouraged to join the class action to seek compensation.
Nano-X Deadline: NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Nano-X Imaging Ltd. (NASDAQ: NNOX) securities that the lead plaintiff deadline for a securities fraud lawsuit is August 11, 2026. Investors who bought Nano-X securities between March 31, 2025, and April 17, 2026, may be entitled to compensation. The lawsuit alleges that Nano-X overstated efficiency and demand, leading to increased operating expenses and potential restructuring charges.
NNOX Investors Have Opportunity to Lead Nano-X Imaging Ltd. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ:NNOX) on behalf of investors who purchased securities between March 31, 2025, and April 17, 2026. The lawsuit alleges that Nano-X made materially false and misleading statements regarding its business operations, specifically overstating efficiency gains and demand for its products, leading to increased operating expenses and potential restructuring. Investors who suffered losses are encouraged to join the case by August 11, 2026, to potentially be appointed as lead plaintiff.
